Developer docs
API playgroundTry for free, no card

Search company profiles

Merus Labs

Full company profile

uuid003pel8

Namestring
Merus Labs
Legal namestring
Norgine
Websiteurl
meruslabs.com
Company typeenum
Private
Founded yearint
1906
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, gastroenterology medicines, hepatology therapeutics, pharmaceutical partnerships, specialist therapy areas
Industry2 codes
1Neurology & CNS Specialty Pharmaceuticals
CodeHLAIACACPrimaryYes
2Infectious Disease & Antimicrobials Pharmaceuticals
CodeHLAIAAAGPrimaryNo
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Norgine generates revenue through the commercialization of specialty pharmaceutical products, with over €500 million in net product sales. The company focuses on acquiring, developing, and commercializing innovative medicines.

norgine.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Norgine is a European specialist pharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical products across multiple therapy areas, primarily gastroenterology and hepatology. The company operates a flexible partnership-driven business model supporting licensing, acquisition, and special purpose vehicle (SPV) arrangements to bring transformative medicines to patients. It commercializes products through an integrated European infrastructure of over 1,400 employees, generating over €500 million in net product sales annually.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 25 million patients helped annually worldwide
Product and service1 record
1Specialty pharmaceutical products (gastroenterology and hepatology portfolio)
CategorySpecialty Pharmaceuticals
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Global Partnership Network
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Norgine maintains a strong global network of partnerships enabling the acquisition, development, and commercialization of innovative pharmaceutical products. Partnership structures include licensing, acquisition, and special purpose vehicle (SPV) arrangements, supporting the company's ability to bring transformative medicines to patients.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Ferring Pharmaceuticals
TypeDirect peer
Description

Ferring is a privately held Swiss specialty pharmaceutical company with a strong focus on gastroenterology and reproductive health. Its European footprint and GI franchise make it one of the closest therapeutic-area peers to Norgine.

2Almirall
TypeDirect peer
Description

Almirall is a Spanish specialty pharmaceutical company focused on dermatology and specialty therapeutics, with a comparable European specialty-pharma commercial model and similar partnership-driven growth approach.

3Dr. Falk Pharma
TypeDirect peer
Description

Dr. Falk Pharma is a German specialty pharmaceutical company with a deep focus on gastroenterology and hepatology, making it the closest direct therapeutic-area competitor to Norgine in the European specialty GI/hepatology space.

4Menarini Group
TypeBroad incumbent
Description

Menarini is a broad Italian pharmaceutical group with significant specialty pharma operations across Europe, including GI and specialty therapeutics. It is comparable as a larger European incumbent operating adjacent specialty categories to Norgine.

5Grünenthal
TypeDirect peer
Description

Grünenthal is a privately held German specialty pharmaceutical company with a European commercial platform and specialty therapy focus, including pain and GI-adjacent areas. Its privately held, mid-sized European specialty model closely mirrors Norgine's positioning.

6Sobi (Swedish Orphan Biovitrum)
TypeDirect peer
Description

Sobi is a Swedish specialty pharmaceutical company focused on rare diseases and specialty therapeutics, with comparable European commercial reach and a similar partnership-and-acquisition-driven growth model to Norgine.

7Tillotts Pharma
TypeEmerging player
Description

Tillotts Pharma is a Swiss specialty pharmaceutical company focused on gastroenterology, representing a more niche European specialty peer in the same therapeutic category as Norgine.

8Ipsen
TypeDirect peer
Description

Ipsen is a French specialty pharmaceutical company of comparable scale focused on specialty care therapeutics across oncology, neurology, and rare diseases, with similar in-licensing and acquisition-driven growth dynamics. Both companies operate as mid-sized European specialty pharma platforms with concentrated therapy area focus.

9Recordati
TypeDirect peer
Description

Recordati is an Italian specialty pharmaceutical group of similar revenue scale with operations across Europe and a focus on specialty therapeutics. Like Norgine, it relies on a mix of proprietary and partnered products and serves European patients through established commercial infrastructure.

10Kyowa Kirin International
TypeDirect peer
Description

Kyowa Kirin International operates a European specialty pharma platform focused on specialty therapeutics including GI-adjacent conditions. Its specialty commercial infrastructure and partnership-led growth make it comparable to Norgine.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Merus Labs

Specialty Pharmaceuticalsmeruslabs.com

Merus Labs firmographics

Firmographics
Name
Merus Labs
Legal name
Norgine
Website
https://meruslabs.com
Company type
Private
Founded year
1906
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Merus Labs industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
akta.pro secondary industry
Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

  • Specialty pharmaceuticals
  • Gastroenterology medicines
  • Hepatology therapeutics
  • Pharmaceutical partnerships
  • Specialist therapy areas

Where Merus Labs is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Merus Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Norgine generates revenue through the commercialization of specialty pharmaceutical products, with over €500 million in net product sales. The company focuses on acquiring, developing, and commercializing innovative medicines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Merus Labs product offering

Product offering

Core offering

Norgine is a European specialist pharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical products across multiple therapy areas, primarily gastroenterology and hepatology. The company operates a flexible partnership-driven business model supporting licensing, acquisition, and special purpose vehicle (SPV) arrangements to bring transformative medicines to patients. It commercializes products through an integrated European infrastructure of over 1,400 employees, generating over €500 million in net product sales annually.

Differentiator

Problem solved

Functional benefit

Products and services

  • Specialty pharmaceutical products (gastroenterology and hepatology portfolio)

Quantifiable outcome

  • 25 million patients helped annually worldwide

Companies that use Merus Labs

Customer profile

Segments1 record

Ideal customer profiles1 record

Merus Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Merus Labs partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Global Partnership NetworkcoreStrategic or Co-development PartnerNorgine maintains a strong global network of partnerships enabling the acquisition, development, and commercialization of innovative pharmaceutical products. Partnership structures include licensing, acquisition, and special purpose vehicle (SPV) arrangements, supporting the company's ability to bring transformative medicines to patients.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Merus Labs competitors and assessment

Company assessment

Direct peers

  • Ferring Pharmaceuticals: Ferring is a privately held Swiss specialty pharmaceutical company with a strong focus on gastroenterology and reproductive health. Its European footprint and GI franchise make it one of the closest therapeutic-area peers to Norgine.
  • Almirall: Almirall is a Spanish specialty pharmaceutical company focused on dermatology and specialty therapeutics, with a comparable European specialty-pharma commercial model and similar partnership-driven growth approach.
  • Dr. Falk Pharma: Dr. Falk Pharma is a German specialty pharmaceutical company with a deep focus on gastroenterology and hepatology, making it the closest direct therapeutic-area competitor to Norgine in the European specialty GI/hepatology space.
  • Grünenthal: Grünenthal is a privately held German specialty pharmaceutical company with a European commercial platform and specialty therapy focus, including pain and GI-adjacent areas. Its privately held, mid-sized European specialty model closely mirrors Norgine's positioning.
  • Sobi (Swedish Orphan Biovitrum): Sobi is a Swedish specialty pharmaceutical company focused on rare diseases and specialty therapeutics, with comparable European commercial reach and a similar partnership-and-acquisition-driven growth model to Norgine.
  • Ipsen: Ipsen is a French specialty pharmaceutical company of comparable scale focused on specialty care therapeutics across oncology, neurology, and rare diseases, with similar in-licensing and acquisition-driven growth dynamics. Both companies operate as mid-sized European specialty pharma platforms with concentrated therapy area focus.
  • Recordati: Recordati is an Italian specialty pharmaceutical group of similar revenue scale with operations across Europe and a focus on specialty therapeutics. Like Norgine, it relies on a mix of proprietary and partnered products and serves European patients through established commercial infrastructure.
  • Kyowa Kirin International: Kyowa Kirin International operates a European specialty pharma platform focused on specialty therapeutics including GI-adjacent conditions. Its specialty commercial infrastructure and partnership-led growth make it comparable to Norgine.

Broad incumbents

  • Menarini Group: Menarini is a broad Italian pharmaceutical group with significant specialty pharma operations across Europe, including GI and specialty therapeutics. It is comparable as a larger European incumbent operating adjacent specialty categories to Norgine.

Emerging players

  • Tillotts Pharma: Tillotts Pharma is a Swiss specialty pharmaceutical company focused on gastroenterology, representing a more niche European specialty peer in the same therapeutic category as Norgine.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Merus Labs social profiles

Digital presence

Merus Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Merus Labs leadership team

Management profile

Number of profiles

Merus Labs funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Merus Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merus Labs

What does Merus Labs do?

Norgine is a European specialist pharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical products across multiple therapy areas, primarily gastroenterology and hepatology. The company operates a flexible partnership-driven business model supporting licensing, acquisition, and special purpose vehicle (SPV) arrangements to bring transformative medicines to patients. It commercializes products through an integrated European infrastructure of over 1,400 employees, generating over €500 million in net product sales annually.

Is Merus Labs a public or private company?

Merus Labs is a private company. It is classified as unknown and is currently operating.

When was Merus Labs founded?

Merus Labs was founded in 1906. It employs 11 to 50 people.

Where is Merus Labs based?

Merus Labs is headquartered in Toronto, Canada, in the North America region.

How does Merus Labs make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Merus Labs's main competitors?

Direct peers on record are Ferring Pharmaceuticals, Almirall, Dr. Falk Pharma, Grünenthal, Sobi (Swedish Orphan Biovitrum), Ipsen, Recordati and Kyowa Kirin International. Menarini Group is listed as a broad incumbent. Tillotts Pharma is listed as an emerging player.

Does Merus Labs have an API?

No public API is recorded for Merus Labs.

What industry is Merus Labs in?

Merus Labs's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsEquities Analysts Issue Forecasts for TSE:MSL Q3 EarningsEquities research analysts at HC Wainwright lowered their Q3 2026 earnings per share estimate for Merus Labs International to ($0.60) from a previous forecast of ($0.49). Other analysts, including Guggenheim and Canaccord Genuity Group, have recently upgraded the stock with 'strong-buy' and 'moderate buy' ratings respectively. The company remains a specialty pharmaceutical firm engaged in acquiring and licensing branded prescription products.Defense WorldMerus Labs International (TSE:MSL) Raised to “Strong-Buy” at Leerink PartnersAnalysts at Leerink Partners and Cantor Fitzgerald both upgraded Merus Labs International to a "strong-buy" rating in separate reports issued this week, with the stock currently holding an average rating of "Strong Buy" across two analysts. Merus Labs International is a specialty pharmaceutical company engaged in the acquisition and licensing of branded prescription pharmaceutical products, trading on the Toronto Stock Exchange and NASDAQ.Defense WorldEquities Analysts Offer Predictions for TSE:MSL Q1 EarningsHC Wainwright lowered its Q1 2026 earnings forecast for Merus Labs International to a loss of $0.50 per share, down from its prior estimate of $0.48, while also issuing revised estimates for Q2-Q4 2026 and full-year forecasts through 2030. Separately, Cantor Fitzgerald upgraded the company's shares to a "strong-buy" rating on March 11th, with the stock currently holding an average "Strong Buy" rating across one analyst. Merus Labs International is a specialty pharmaceutical company engaged in acquiring and licensing branded prescription pharmaceutical products.Defense WorldBrokers Issue Forecasts for TSE:MSL Q1 EarningsEquity research analysts at HC Wainwright issued Q1 2027 earnings per share estimates for Merus Labs International Inc., forecasting a loss of ($0.56) per share, with further losses projected through Q4 2027. Cantor Fitzgerald simultaneously upgraded the specialty pharmaceutical company's stock to a "strong-buy" rating in a separate report. Merus Labs International operates in the branded prescription pharmaceutical products sector, with its stock trading on both the Toronto Stock Exchange and NASDAQ.PR NewswireNorgine B.V. desinvierte sus activos canadienses adquiridos por medio de Merus Labs International Inc.Norgine B.V. has completed the divestiture of its Canadian assets, originally acquired through Merus Labs International Inc. in July 2017, to Searchlight Pharma Inc. for an undisclosed amount. Searchlight Pharma assumes immediate ownership and distribution of Enablex® (darifenacine) and Vancocin® (vancomycin) in Canada, products that generated 3.4 million euros (5.1 million Canadian dollars) in sales for the 12 months ending December 2017. Norgine will use proceeds to fund acquisitions of specialist products for its European operations while maintaining all assets outside of Canada.PR NewswireNorgine B.V. cédera ses actifs canadiens acquis par l'entremise de Merus Labs International Inc. à Pharmaceutique SearchlightPharmaceutique Searchlight Inc. has acquired the Canadian assets of Merus Labs International Inc., a subsidiary of Norgine B.V., including the rights to distribute Enablex and Vancocin in Canada. Norgine will retain its non-Canadian assets as part of its strategy to focus on the European market, while Searchlight integrates these products into its portfolio to expand its presence in urology markets.PR NewswireNorgine B.V. veräußert kanadische Anlagen aus dem Erwerb von Merus Labs International Inc. an Searchlight PharmaNorgine B.V. completed the sale of Canadian assets from its 2017 acquisition of Merus Labs International Inc. to Searchlight Pharma Inc. for an undisclosed amount. Searchlight Pharma assumes immediate ownership and responsibility for marketing Enablex® (darifenacin) and Vancocin® (vancomycin) in Canada, while Norgine retains all assets outside the Canadian market. The Merus Canadian business generated approximately €3.4 million (CAD 5.1 million) in sales over the 12 months ending December 2017, according to IQVIA CDH data.PR NewswireNorgine B.V. completes acquisition of Merus Labs International Inc. strengthening its leading position in the European specialist pharma marketNorgine B.V. has completed its acquisition of Merus Labs International Inc. through a court-approved plan of arrangement, making Merus a wholly-owned subsidiary of Norgine. The transaction valued at approximately C$342 million gives Norgine a portfolio of 12 established pharmaceutical products, including brands such as SINTROM, VANCOCIN, and ESTRADERM, with Merus reporting C$111.4 million in product sales for fiscal year 2016. The acquisition strengthens Norgine's position as a leading European specialist pharma company and is expected to increase its scale and profitability.PR NewswireNorgine B.V. completa la adquisición de Merus Labs International Inc.Norgine B.V. completed the acquisition of Merus Labs International Inc. for approximately 342 million Canadian dollars (1.65 CAD per share). Through this transaction, Norgine acquired a portfolio of 12 established pharmaceutical products including brands like SINTROM, VANCOCIN, and others sold in European and selected markets. Merus, with approximately 22 employees and fiscal year 2016 product sales of 111.4 million Canadian dollars, becomes a wholly-owned subsidiary of Norgine, strengthening Norgine's position as a leading European specialty pharmaceutical company.PR NewswireMerus Labs International Inc. Receives Court Approval in Connection with Proposed Plan of Arrangement with Norgine B.V.The Supreme Court of British Columbia issued a final order on July 12, 2017 approving Norgine B.V.'s acquisition of all outstanding common shares of Merus Labs International Inc. through a plan of arrangement. The transaction remains conditional on closing conditions and is anticipated to close on July 17, 2017. Merus is a specialty pharmaceutical company focused on acquiring and optimizing products across Europe, Canada and select markets, while Norgine is a European specialist pharmaceutical company with €368 million in 2016 revenue and operations across major European markets.